New Antibody-Drug conjugate targets Hard-to-Treat cancers

NCT ID NCT07145255

Recruiting now Disease control Sponsor: MBrace Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new drug called MBRC-201 in people with advanced solid tumors (prostate, breast, colorectal, lung, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The trial has three parts: first, finding the safest dose; second, expanding to more patients; and third, testing effectiveness. About 150 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MBRC-201 (an antibody-drug conjugate)
What this could lead to: If successful, this could point toward a new treatment option for advanced cancers that have not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or may have significant side effects. It is not a cure and requires ongoing disease management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm castration-resistant prostate carcinoma colonic neoplasm colorectal cancer colorectal neoplasm HER2 positive breast carcinoma hormone receptor-positive breast cancer lung cancer non-small cell lung carcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm prostate cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER COLO-RECTAL CANCER LUNG CANCER (NON-SMALL CELL) PANCREAS CANCER, DUCT CELL ADENOCARCINOMA PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

NEXT, Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT, Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
START, Astera
RECRUITING

East Brunswick, New Jersey, 08816, United States
START, Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START, Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITING

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.